A Fernandez Montes1, F Vazquez Rivera2, N Martinez Lago3, M Covela Rúa4, A Cousillas Castiñeiras5, P Gonzalez Villarroel6, J de la Cámara Gómez7, J C Méndez Méndez8, M Salgado Fernández9, S Candamio Folgar2, M Reboredo López3, M Carmona Campos4, E Gallardo Martín10, M Jorge Fernández6, M L Pellón Augusto7, L París Bouzas8, J García Gómez11. 1. Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, C/Calle Ramon Puga Noguerol, 54, s/n, 32005, Ourense, Spain. afm1003@hotmail.com. 2. Medical Oncology Department, Hospital Clínico Universitario de Santiago, Rúa da Choupana, s/n, 15706, Santiago, A Coruña, Spain. 3. Medical Oncology Department, Hospital Universitario A Coruña, C/As Xubias, s/n, 15006, A Coruña, Spain. 4. Medical Oncology Department, Hospital Universitario Lucus Augusti, C/Dr. Ulises Romero, 1, 27003, Lugo, Spain. 5. Medical Oncology Department, Hospital Provincial de Pontevedra, C/Loureiro Crespo, 2, 36002, Pontevedra, Spain. 6. Medical Oncology Department, Hospital Universitario Álvaro Cunqueiro, C/Estrada de Clara Campoamor, 341, 36312, Vigo, Pontevedra, Spain. 7. Medical Oncology Department, Hospital Universitario Arquitecto Marcide, Av. da Residencia, s/n, 15405, El Ferrol, A Coruña, Spain. 8. Medical Oncology Department, Centro Oncológico de Galicia, Rúa Doctor Camilo Veiras, 1, 15009, A Coruña, Spain. 9. Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, C/Ramón Puga, s/n, 32005, Ourense, Spain. 10. Medical Oncology Department, Hospital Provincial de Pontevedra,, C/Loureiro Crespo, 2, 36002, Pontevedra, Spain. 11. Medical Oncology Department, Complexo Hospitalario Universitario de Ourense,, C/Calle Ramon Puga Noguerol, s/n, 32005, Ourense, Spain.
Abstract
INTRODUCTION: Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC). We evaluated the efficacy and safety of this combination in the real-life setting at eight Galician centers in Spain. PATIENTS AND METHODS: This is a retrospective study of a cohort of patients with mCRC in treatment with trifluridine/tipiracil within usual clinical practice who have been previously treated or are not considered candidates for treatment with available therapies. RESULTS: A total of 160 mCRC patients were included. Our data showed that 11.9% of patients achieved disease control. Median progression-free survival was 2.75 months; at 5.66 months follow-up, median overall survival was 7.94 months. Asthenia and neutropenia (48.1% both) were the most frequent adverse events. Overall survival was lower in patients with ECOG 2, multiple metastatic sites, platelets count 350,000/µl, alkaline phosphatase > 500 IU/l, and carcinoembryonic antigen > 10 ng/ml. CONCLUSION: The results of this study confirm the efficacy and safety of trifluridine/tipiracil in chemorefractory mCRC patients. However, patients in clinical practice differ from patients in clinical trials. Due to this, prognostic factors have special importance to offer the best therapeutic approach.
INTRODUCTION:Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC). We evaluated the efficacy and safety of this combination in the real-life setting at eight Galician centers in Spain. PATIENTS AND METHODS: This is a retrospective study of a cohort of patients with mCRC in treatment with trifluridine/tipiracil within usual clinical practice who have been previously treated or are not considered candidates for treatment with available therapies. RESULTS: A total of 160 mCRC patients were included. Our data showed that 11.9% of patients achieved disease control. Median progression-free survival was 2.75 months; at 5.66 months follow-up, median overall survival was 7.94 months. Asthenia and neutropenia (48.1% both) were the most frequent adverse events. Overall survival was lower in patients with ECOG 2, multiple metastatic sites, platelets count 350,000/µl, alkaline phosphatase > 500 IU/l, and carcinoembryonic antigen > 10 ng/ml. CONCLUSION: The results of this study confirm the efficacy and safety of trifluridine/tipiracil in chemorefractory mCRC patients. However, patients in clinical practice differ from patients in clinical trials. Due to this, prognostic factors have special importance to offer the best therapeutic approach.
Authors: L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller Journal: N Engl J Med Date: 2000-09-28 Impact factor: 91.245
Authors: J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray Journal: Eur J Cancer Date: 2013-02-26 Impact factor: 9.162
Authors: Michael J Overman; Scott Kopetz; Gauri Varadhachary; Masakazu Fukushima; Keizo Kuwata; Akira Mita; Robert A Wolff; Paulo Hoff; Henry Xiong; James L Abbruzzese Journal: Cancer Invest Date: 2008-10 Impact factor: 2.176
Authors: Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent Journal: Lancet Date: 2012-11-22 Impact factor: 79.321